A5091850279- Antibiotics Pharmacokinetics and Efficacy
- Innovations in Medical Education
- HIV, Drug Use, Sexual Risk
- Empathy and Medical Education
- Hepatitis C virus research
- Ethics and Legal Issues in Pediatric Healthcare
- Chronic Kidney Disease and Diabetes
- Biomedical and Engineering Education
- Diversity and Career in Medicine
- Clinical Reasoning and Diagnostic Skills
- Pharmacy and Medical Practices
- Pharmaceutical studies and practices
- Diabetes Treatment and Management
- Pharmaceutical Practices and Patient Outcomes
- Polyomavirus and related diseases
- Biosimilars and Bioanalytical Methods
- Metabolism and Genetic Disorders
- Pneumonia and Respiratory Infections
- Viral-associated cancers and disorders
- Patient Dignity and Privacy
- Surgical Simulation and Training
- Vaccine Coverage and Hesitancy
- Nausea and vomiting management
- Neutropenia and Cancer Infections
- Drug-Induced Hepatotoxicity and Protection
Midwestern University
2024
University of Arkansas for Medical Sciences
2020-2021
CARE Canada
2021
University of Miami
2019-2020
Brown University
2007
OBJECTIVES: To examine the role of advance directives (ADs) 10 years after Patient Self‐Determination Act. DESIGN: Mortality follow‐back survey. SETTING: People who died in a nursing home, hospital, or at home. PARTICIPANTS: Bereaved family member other knowledgeable informant. MEASUREMENTS: Telephone interviewers that asked about use written ADs, life‐sustaining treatment, and quality care by asking whether staff provided desired symptom relief, treated dying with respect, supported shared...
Abstract Background Efficacy for prolonged infusion beta-lactam dosing schemes has been previously described, but there less focus on the safety of standard vs protocols beta-lactams. This study explored differences in adverse drug reactions (ADRs) reported beta-lactams between each these protocols. Methods A systematic review MEDLINE literature databases via PubMed was conducted and references were compiled. Articles compiled assessed with specific inclusion/exclusion criteria. We included...
91 Background: Biosimilar agents are changing the clinical landscape in oncology. We sought to measure oncologists’ competence and knowledge of biosimilars address identified educational gaps related biosimilars’ application. Methods: designed a 2-phase online program focused on that included questions competence. These were administered before then repeated after education was delivered. Oncologists also invited submit their own about use practice. To uncover key gaps, we with high...
Though the rhetoric of this passage from Daybreak may suggest Nietzsche is somehow opposed to pity/compassion (Mitleid), substantive claim descriptive rather than prescriptive. has much say elsewhere about value compassion,1 but in excerpt, he focuses on its nature, arguing that compassion not simple, unconditional, or selfless. His description resonate with physicians and medical educators, at a moment when there purportedly crisis medicine2 our desire teach capacity seems have outpaced...
Abstract Background Clinicians often encounter patients requiring simultaneous treatment for both HIV and HCV. Although several resources help clinicians identify potential drug interactions, these do not account other factors that should be considered when selecting HCV regimens, such as renal function, HLA-B*5701 status, genotype. We developed an online decision support tool based on guideline recommendations. report data comparing recommendations with the initial plans of using tool....
Abstract Background The AASLD HBV management guidelines were updated in 2018 to include new recommendations. Patient variables that inform treatment candidacy and selection are complex interconnected. To aid healthcare practitioners (HCPs) aligning decisions with practice guidance, we developed a Web- app-based decision support tool, Hep B Consult. Methods tool enables users specify guideline (AASLD, EASL, or APASL) prompts them enter patient variables: DNA/ALT levels, liver fibrosis,...
Abstract Background: T2D management is shifting toward treating patients with therapies that align their level of CV and end-organ risk. To this end, evidence-based guidelines now recommend glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for both glycemic extraglycemic benefits. The great speed which these recommendations change create immediate gaps in knowledge competence, especially as they relate to managing comorbid and/or renal disease. help clinicians understand GLP-1 RA novel...